Simcere Pharmaceutical Group is an emerging leader in developing, manufacturing, and marketing pharmaceutical products in China. It has over 3,000 sales reps covering over 3,000 hospitals and 70,000 retail pharmacies. Simcere focuses on five therapeutic areas and has differentiated products with market leadership in oncology and neuroscience. It has strong R&D capabilities and pursues an externalization strategy through licensing, collaborations, and acquisitions to develop a sustainable pipeline.
Financial report 2005 taj pharmaceuticals groupShantanu Singh
Taj Pharma Group reported financial results for the year ended March 31, 2005. Net sales increased by over 33% to Rs. 79,368 lacs from Rs. 59,578 lacs in 2004. Gross profit increased by over 45% to Rs. 46,958 lacs compared to Rs. 32,225 lacs in the prior year. Operating income grew 51% to Rs. 20,132 lacs in 2005 from Rs. 13,318 lacs in 2004, despite higher selling, general and administrative expenses as well as non-recurring operating expenses.
Financial report 2010 taj pharmaceuticals groupShantanu Singh
Taj Pharma Group reported financial results for the year ended March 31, 2010. Net sales increased to $79.4 billion from $59.6 billion in 2009. Gross profit increased to $47 billion from $32.2 billion in 2009. Operating income increased to $20.1 billion from $13.3 billion in 2009. Income before income tax expense increased to $18.5 billion from $11.4 billion in 2009.
Creating Great Content for Both Search Engines and HumansJessica Lee
This document discusses optimizing web content for both users and search engines. It begins by explaining why content optimization is important, noting that both users and search engines like Google value high-quality, original content. It then covers best practices for content optimization, including defining the purpose and audience for pages, researching keywords, and incorporating keywords naturally into pages. The document concludes by discussing specific technical elements like meta data, body content, headers, and formatting to help content be found and engaged with.
The document provides guidelines from Hill & Knowlton for organizations to prepare pandemic preparedness plans. It outlines 4 steps for organizations: 1) scenario planning and revision, 2) plan testing through desktop simulations, 3) pandemic communications training, and 4) implementing the pandemic response plan if needed. Hill & Knowlton offers services to help organizations develop and test their plans, train spokespeople, and implement response strategies if a pandemic occurs.
The document provides guidelines from Hill & Knowlton for organizations to develop and test pandemic preparedness plans. It outlines 4 steps for initiating a plan: 1) scenario planning and revision, 2) plan testing through desktop simulations, 3) pandemic communications training, and 4) implementing the plan in the event of an escalating pandemic threat. Hill & Knowlton offers services to help organizations develop response strategies, communication materials, media liaison activities, and other support. The overall message is that pandemic preparedness planning is essential for organizations to be able to respond properly and minimize disruption during a health crisis.
Financial report 2005 taj pharmaceuticals groupShantanu Singh
Taj Pharma Group reported financial results for the year ended March 31, 2005. Net sales increased by over 33% to Rs. 79,368 lacs from Rs. 59,578 lacs in 2004. Gross profit increased by over 45% to Rs. 46,958 lacs compared to Rs. 32,225 lacs in the prior year. Operating income grew 51% to Rs. 20,132 lacs in 2005 from Rs. 13,318 lacs in 2004, despite higher selling, general and administrative expenses as well as non-recurring operating expenses.
Financial report 2010 taj pharmaceuticals groupShantanu Singh
Taj Pharma Group reported financial results for the year ended March 31, 2010. Net sales increased to $79.4 billion from $59.6 billion in 2009. Gross profit increased to $47 billion from $32.2 billion in 2009. Operating income increased to $20.1 billion from $13.3 billion in 2009. Income before income tax expense increased to $18.5 billion from $11.4 billion in 2009.
Creating Great Content for Both Search Engines and HumansJessica Lee
This document discusses optimizing web content for both users and search engines. It begins by explaining why content optimization is important, noting that both users and search engines like Google value high-quality, original content. It then covers best practices for content optimization, including defining the purpose and audience for pages, researching keywords, and incorporating keywords naturally into pages. The document concludes by discussing specific technical elements like meta data, body content, headers, and formatting to help content be found and engaged with.
The document provides guidelines from Hill & Knowlton for organizations to prepare pandemic preparedness plans. It outlines 4 steps for organizations: 1) scenario planning and revision, 2) plan testing through desktop simulations, 3) pandemic communications training, and 4) implementing the pandemic response plan if needed. Hill & Knowlton offers services to help organizations develop and test their plans, train spokespeople, and implement response strategies if a pandemic occurs.
The document provides guidelines from Hill & Knowlton for organizations to develop and test pandemic preparedness plans. It outlines 4 steps for initiating a plan: 1) scenario planning and revision, 2) plan testing through desktop simulations, 3) pandemic communications training, and 4) implementing the plan in the event of an escalating pandemic threat. Hill & Knowlton offers services to help organizations develop response strategies, communication materials, media liaison activities, and other support. The overall message is that pandemic preparedness planning is essential for organizations to be able to respond properly and minimize disruption during a health crisis.
The best stock broker and share broker in India, Rudra Shares & Stock Brokers Ltd. is member of all the leading Equity & commodity exchanges in India, dealing in stocks, shares, commodity & currency serving clientele in 18 states through 225 business partners. Rudra Shares Positional Call Report which will brief about
Ipca Laboratories Ltd.
Natco Pharma Limited is an integrated pharmaceutical company with operations across India, the US, and rest of world. It has a strong brand presence in oncology in India and is growing its portfolio in cardiology and diabetes. The company focuses on complex generics for the US market through niche Paragraph IV and Paragraph III filings. It has two R&D centers with over 525 employees and is poised for growth in the agricultural chemicals space. For the financial year ending March 2021, Natco Pharma reported total revenues of INR 21,557 million.
Financial report 2004 taj pharmaceuticals groupShantanu Singh
Taj Pharmaceuticals Limited is an India-based pharmaceutical business. In 2004, the company reported net sales of 57,859 rupees with a gross profit of 32,225 rupees. Selling, general and administrative expenses totaled 19,529 rupees. The company reported net income of 10,111 rupees for the year. Taj believes in environmental stewardship and considers safety and environmental protection as obligations in its business dealings.
Tata Sponge Iron Limited is one of India's largest merchant sponge iron manufacturers and a subsidiary of Tata Steel. It manufactures sponge iron using the TDR technology and also generates power from waste heat for captive use and third party sale. The company has a manufacturing capacity of 390,000 MTPA of sponge iron and a power generation capacity of 26 MW. It is strategically located near iron ore mines in Odisha which provides operational and logistical advantages. The company has demonstrated robust financial and market performance over the years with growing revenues, expanding margins, consistent profitability and dividend payouts.
Financial report 2006 taj pharmaceuticals groupShantanu Singh
This document provides financial reports for Taj Pharmaceuticals Limited for the year ending March 31, 2006. It includes the consolidated income statement, balance sheet, statement of cash flows, and statement of changes in equity. The income statement shows revenues of Rs. 100,462 lacs and net income of Rs. 18,357 lacs. The balance sheet lists total assets of Rs. 125,235 lacs, including non-current assets of Rs. 40,244 lacs and total equity and liabilities of Rs. 125,235 lacs, including total equity of Rs. 87,322 lacs.
Business Plan- TLG Resources International LLCnroopraj24
This document provides an overview of T.L.G. Resources International's business plan. T.L.G. facilitates the procurement of Active Pharmaceutical Ingredients for pharmaceutical companies in the United States. It aims to become a leading supply chain enabler for sourcing internationally produced APIs. The business plan outlines T.L.G.'s services, the growing US pharmaceutical market, trends in the API supply chain industry, potential customers in the therapeutic drug categories with the largest market share, and projected strong financial performance over the first three years of operations.
Financial report 2008 taj pharmaceuticals groupShantanu Singh
1) The document appears to be Taj Pharmaceuticals Limited's 2008 financial report.
2) It includes Taj Pharmaceuticals Limited's consolidated income statement for the year ending March 31, 2008, showing revenues and expenses in Indian rupees and lakhs.
3) The report discloses forward-looking statements about Taj Pharmaceuticals Limited's strategy, financial position, operations, and development of products.
- Quintiles provides clinical research and integrated healthcare services to the biopharmaceutical and healthcare industries.
- They are the largest contract research organization in terms of backlog and market share.
- In this presentation, Quintiles discusses their strong financial performance, large backlog providing revenue visibility, leadership in key markets, and strategy to capitalize on trends in the biopharma industry to drive continued growth.
The Health & Wellness market in the UK was valued at £23bn in 2020, an increase from £20.5bn in 2015. Total healthcare, wellness and fitness spending in the UK reached £209bn in 2020. Pure Restore Health provides innovative treatments and therapies utilizing the latest healthcare technologies to help people feel their best by addressing issues like chronic pain, injury recovery, athletic performance and more.
Marpai is an AI tech company revolutionizing the self-funded health plan
market representing over $1 trillion in health claims, $20 billion in
administrative fees, and 95 million Americans. Just as Netflix, Amazon,
Uber, and Tesla use artificial intelligence to transform and lead industry
sectors, Marpai (pronounced Mar-pay) is using deep learning, the most
advanced artificial intelligence, to transform health plan administration
for companies who self-fund their health plans. As a next-generation
TPA (Third Party Administrator) using SMART technology (deeplearning powered), Marpai’s mission is to save lives, improve lives, and
radically reduce the costs of healthcare for employers and plan
members.
Daily Derivatives Report:21 February 2019Axis Direct
Axis Direct presents daily derivatives report presenting recommendations based on technical analysis. For trading in derivatives visit https://simplehai.axisdirect.in/offerings/products/derivatives
This document provides information on the top 10 holdings of the HAN-GINS Indxx Healthcare Innovation UCITS ETF as of 21st March 2019. The largest holding is Illumina, a developer of life science tools and DNA sequencing systems, at 5.5%. The other top holdings include Boston Scientific, Medtronic, Intuitive Surgical, Biogen and others in the medical device and healthcare industries. Contact information is provided for HANetf.
Daily Derivatives Report:15 February 2019Axis Direct
The daily derivative report dated 15 February 2019 provides a summary of the performance of Nifty futures and options. Some key highlights from the report include:
- Nifty futures closed at 10,779.80 points on a negative note with a 4.96% decrease in open interest, indicating long unwinding.
- FIIs were net sellers in the derivative segment to the tune of Rs. 1,745 crores.
- The India VIX index is at 15.77 and the Nifty ATM call IV is at 14.07 while the put IV is at 13.09.
- In stock futures, long build up was seen in LT, IGL, DCBBANK and CON
The board of directors of Fortis Healthcare Limited (Fortis Healthcare) has approved a composite scheme of arrangement and amalgamation which would result in the demerger of the company’s diagnostic business, primarily housed in its majority owned subsidiary SRL Limited (SRL), into another majority owned listed subsidiary, Fortis Malar Hospitals Limited (Fortis Malar), followed by SRL being merged into Fortis Malar as part of the same Composite Scheme.
Source:http://www.fortishealthcare.com/india/press/fortis-healthcare-limited-composite-scheme-379-0
Axis Direct presents daily derivatives report presenting recommendations based on technical analysis. For trading in derivatives visit https://simplehai.axisdirect.in/offerings/products/derivatives
Daily Derivatives Report:09 January 2019Axis Direct
Axis Direct presents daily derivatives report presenting recommendations based on technical analysis. For trading in derivatives visit https://simplehai.axisdirect.in/offerings/products/derivatives
https://simplehai.axisdirect.in/share-stock-prices/nse/ICICI-Bank-Ltd-5418
https://simplehai.axisdirect.in/share-stock-prices/nse/CEAT-Ltd-104
Daily Derivatives Report:13 December 2018Axis Direct
Axis Direct presents daily derivatives report presenting recommendations based on technical analysis. For trading in derivatives visit https://simplehai.axisdirect.in/offerings/products/derivatives
https://simplehai.axisdirect.in/share-stock-prices/nse/Lupin-Ltd-3026
Marel held a Capital Markets Day to provide an overview of the company and its strategy for delivering 12% annual revenue growth globally through digital and sustainable solutions. Marel aims to be a one-stop-shop across poultry, meat, and fish processing with standardized modular equipment, proprietary software, and digital solutions. The company's focus on innovation, excellence, and ESG/sustainability has supported over 20% average annual revenue growth since its 1992 listing.
The best stock broker and share broker in India, Rudra Shares & Stock Brokers Ltd. is member of all the leading Equity & commodity exchanges in India, dealing in stocks, shares, commodity & currency serving clientele in 18 states through 225 business partners. Rudra Shares Positional Call Report which will brief about
Ipca Laboratories Ltd.
Natco Pharma Limited is an integrated pharmaceutical company with operations across India, the US, and rest of world. It has a strong brand presence in oncology in India and is growing its portfolio in cardiology and diabetes. The company focuses on complex generics for the US market through niche Paragraph IV and Paragraph III filings. It has two R&D centers with over 525 employees and is poised for growth in the agricultural chemicals space. For the financial year ending March 2021, Natco Pharma reported total revenues of INR 21,557 million.
Financial report 2004 taj pharmaceuticals groupShantanu Singh
Taj Pharmaceuticals Limited is an India-based pharmaceutical business. In 2004, the company reported net sales of 57,859 rupees with a gross profit of 32,225 rupees. Selling, general and administrative expenses totaled 19,529 rupees. The company reported net income of 10,111 rupees for the year. Taj believes in environmental stewardship and considers safety and environmental protection as obligations in its business dealings.
Tata Sponge Iron Limited is one of India's largest merchant sponge iron manufacturers and a subsidiary of Tata Steel. It manufactures sponge iron using the TDR technology and also generates power from waste heat for captive use and third party sale. The company has a manufacturing capacity of 390,000 MTPA of sponge iron and a power generation capacity of 26 MW. It is strategically located near iron ore mines in Odisha which provides operational and logistical advantages. The company has demonstrated robust financial and market performance over the years with growing revenues, expanding margins, consistent profitability and dividend payouts.
Financial report 2006 taj pharmaceuticals groupShantanu Singh
This document provides financial reports for Taj Pharmaceuticals Limited for the year ending March 31, 2006. It includes the consolidated income statement, balance sheet, statement of cash flows, and statement of changes in equity. The income statement shows revenues of Rs. 100,462 lacs and net income of Rs. 18,357 lacs. The balance sheet lists total assets of Rs. 125,235 lacs, including non-current assets of Rs. 40,244 lacs and total equity and liabilities of Rs. 125,235 lacs, including total equity of Rs. 87,322 lacs.
Business Plan- TLG Resources International LLCnroopraj24
This document provides an overview of T.L.G. Resources International's business plan. T.L.G. facilitates the procurement of Active Pharmaceutical Ingredients for pharmaceutical companies in the United States. It aims to become a leading supply chain enabler for sourcing internationally produced APIs. The business plan outlines T.L.G.'s services, the growing US pharmaceutical market, trends in the API supply chain industry, potential customers in the therapeutic drug categories with the largest market share, and projected strong financial performance over the first three years of operations.
Financial report 2008 taj pharmaceuticals groupShantanu Singh
1) The document appears to be Taj Pharmaceuticals Limited's 2008 financial report.
2) It includes Taj Pharmaceuticals Limited's consolidated income statement for the year ending March 31, 2008, showing revenues and expenses in Indian rupees and lakhs.
3) The report discloses forward-looking statements about Taj Pharmaceuticals Limited's strategy, financial position, operations, and development of products.
- Quintiles provides clinical research and integrated healthcare services to the biopharmaceutical and healthcare industries.
- They are the largest contract research organization in terms of backlog and market share.
- In this presentation, Quintiles discusses their strong financial performance, large backlog providing revenue visibility, leadership in key markets, and strategy to capitalize on trends in the biopharma industry to drive continued growth.
The Health & Wellness market in the UK was valued at £23bn in 2020, an increase from £20.5bn in 2015. Total healthcare, wellness and fitness spending in the UK reached £209bn in 2020. Pure Restore Health provides innovative treatments and therapies utilizing the latest healthcare technologies to help people feel their best by addressing issues like chronic pain, injury recovery, athletic performance and more.
Marpai is an AI tech company revolutionizing the self-funded health plan
market representing over $1 trillion in health claims, $20 billion in
administrative fees, and 95 million Americans. Just as Netflix, Amazon,
Uber, and Tesla use artificial intelligence to transform and lead industry
sectors, Marpai (pronounced Mar-pay) is using deep learning, the most
advanced artificial intelligence, to transform health plan administration
for companies who self-fund their health plans. As a next-generation
TPA (Third Party Administrator) using SMART technology (deeplearning powered), Marpai’s mission is to save lives, improve lives, and
radically reduce the costs of healthcare for employers and plan
members.
Daily Derivatives Report:21 February 2019Axis Direct
Axis Direct presents daily derivatives report presenting recommendations based on technical analysis. For trading in derivatives visit https://simplehai.axisdirect.in/offerings/products/derivatives
This document provides information on the top 10 holdings of the HAN-GINS Indxx Healthcare Innovation UCITS ETF as of 21st March 2019. The largest holding is Illumina, a developer of life science tools and DNA sequencing systems, at 5.5%. The other top holdings include Boston Scientific, Medtronic, Intuitive Surgical, Biogen and others in the medical device and healthcare industries. Contact information is provided for HANetf.
Daily Derivatives Report:15 February 2019Axis Direct
The daily derivative report dated 15 February 2019 provides a summary of the performance of Nifty futures and options. Some key highlights from the report include:
- Nifty futures closed at 10,779.80 points on a negative note with a 4.96% decrease in open interest, indicating long unwinding.
- FIIs were net sellers in the derivative segment to the tune of Rs. 1,745 crores.
- The India VIX index is at 15.77 and the Nifty ATM call IV is at 14.07 while the put IV is at 13.09.
- In stock futures, long build up was seen in LT, IGL, DCBBANK and CON
The board of directors of Fortis Healthcare Limited (Fortis Healthcare) has approved a composite scheme of arrangement and amalgamation which would result in the demerger of the company’s diagnostic business, primarily housed in its majority owned subsidiary SRL Limited (SRL), into another majority owned listed subsidiary, Fortis Malar Hospitals Limited (Fortis Malar), followed by SRL being merged into Fortis Malar as part of the same Composite Scheme.
Source:http://www.fortishealthcare.com/india/press/fortis-healthcare-limited-composite-scheme-379-0
Axis Direct presents daily derivatives report presenting recommendations based on technical analysis. For trading in derivatives visit https://simplehai.axisdirect.in/offerings/products/derivatives
Daily Derivatives Report:09 January 2019Axis Direct
Axis Direct presents daily derivatives report presenting recommendations based on technical analysis. For trading in derivatives visit https://simplehai.axisdirect.in/offerings/products/derivatives
https://simplehai.axisdirect.in/share-stock-prices/nse/ICICI-Bank-Ltd-5418
https://simplehai.axisdirect.in/share-stock-prices/nse/CEAT-Ltd-104
Daily Derivatives Report:13 December 2018Axis Direct
Axis Direct presents daily derivatives report presenting recommendations based on technical analysis. For trading in derivatives visit https://simplehai.axisdirect.in/offerings/products/derivatives
https://simplehai.axisdirect.in/share-stock-prices/nse/Lupin-Ltd-3026
Marel held a Capital Markets Day to provide an overview of the company and its strategy for delivering 12% annual revenue growth globally through digital and sustainable solutions. Marel aims to be a one-stop-shop across poultry, meat, and fish processing with standardized modular equipment, proprietary software, and digital solutions. The company's focus on innovation, excellence, and ESG/sustainability has supported over 20% average annual revenue growth since its 1992 listing.
Similar to Simcere Company Presentation 2011.9 (20)
2. Disclaimer
The information contained in this presentation does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer
to buy or subscribe for any securities nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment
whatsoever. Any public offering of the securities to be made in the United States will be made solely by means of the prospectus in the registration
statement. The prospectus contains detailed information about the Company and its management as well as the financial statements of the Company.
Any decision to purchase securities in the offering for sale in the United States or anywhere else should be made solely on the basis of the information
contained in the prospectus. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect
to the risks and special considerations involved with an investment in the securities of the Company, and is qualified in its entirety by reference to the
detailed information appearing in the prospectus.
This presentation contains forward-looking statements, including statements about the Company’s business outlook, our strategy and market opportunity,
and statements about the Company’s historical results that may suggest trends for its business. These statements are individually and collectively
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are made only as of the date of this presentation and the Company undertakes no obligation to update or revise.
These statements are based on estimates and information available to the Company at the time of this presentation and are not guarantees of future
performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Therefore, prospective investors are cautioned
that actual results may differ materially from those set forth in any forward-looking statements herein.
The information contained in these slides has not been independently verified. No representation or warranty, express or implied, is made as to, and no
reliance should be placed on, the fairness, accuracy, completeness or correctness of any information or opinion contained herein. The information
contained in these slides should be considered in the context of the circumstances prevailing at the time and has not been, and will not be, updated to
reflect material developments which may occur after the date of the presentation. None of the Company, any underwriter of securities of the Company, or
any of their respective directors, officers, employees, agents or advisers shall be in any way responsible for the contents hereof, or shall be liable for any
loss arising from use of the information contained in this presentation or otherwise arising in connection therewith.
Before you invest, you should read the prospectus in the registration statement the Company filed with SEC and other documents the Company has filed
with the SEC for more complete information about the Company and this offering. You may get these documents for free by visiting EDGAR on the SEC
Web site at www.sec.gov. Alternatively, you may request the prospectus by sending us a request via our website at www.simcere.com.
2
3. Company Snapshot
Publicly listed on NYSE, with highest standard of corporate compliance and transparency
~3000 sales reps and 1,500 distributors, covering over 3,000 hospitals and 70,000 retail
pharmacies
Leading R&D capabilities in China ranging from early stage discovery to clinical operations
8 GMP facilities supporting small molecule, biologics, and vaccine manufacturing
3
4. A Leader in China’s Pharmaceutical
Industry
Revenue (M, RMB)
2,500
Ranking:
2141
2,000
1850
#21 in Net Profit in
1741 China
healthcare
1,500 industry*
1369
#7 among the Top
1,000 951 20 most
competitive
737
public listed
564
466
healthcare
500
304
companies in
China
0
2002 2003 2004 2005 2006 2007 2008 2009 2010
* 2009 Chinese Medical Statistical Yearbook by Ministry of Industry and Information Technology of PRC
4
5. Key Strategy
Focus on five therapeutic areas in the mid to high-end markets
Oncology, Neuroscience, Cardiovascular, Inflammation, and Infectious
Disease
Leveraged on deep channel penetration and branding advantage to
expand generic market
Strengthening in-house R&D capabilities and cross boarder
collaboration to develop products quickly and effectively
Executing Our Product-Oriented M&A Strategy
5
6. Differentiated Products with Market Leadership in
Oncology and CNS
Therapeutic Area Brand Name Product
Endu Proprietary recombinant human endostatin injection, NSCLC
Jiebaishu Nedaplatin injection
Oncology Sinofuan 5FU sustained release implant
Jiebaili Pemetrexed
Lowvo Palonosetron
Neuroscience Bicun/Yidasheng Edaravone injection, ischemic stroke
Xinta Levamlodipine besylate tablets, hypertension
Cardiovascular
Shufutan Rotuvastain generics, hyperlipidemia
Infectious Disease Anxin Biapenem injection, bacterial infection
I
Yingtaiqing Diclofenac sodium delayed release capsules , arthritis pain
nflammation
6
7. Strong Commercial Muscle and Deep Channel
Penetration
Proven Ability To Quickly
- Select and Position Product - Generate Strong Sales - Build Up Brand and Loyalty
• Collaborating with distributors who have direct selling to the end customers
• Continuing to build up our well trained professional sales team
• Cooperating with nation wide top drug store chains
• Seeking opportunities to leverage on the healthcare reform
Large field force with broad geographical reach
Over 3,000 hospitals Over 70,000 retail
pharmacies
7
9. With Increasing Focus on Novel Products
Category Contribution to Revenue
2005 2006 2007 2008
9
10. Endu: Proprietary Molecular Targeted
Therapy for NSCLC
rh-Endostatin with nine
additional AAs at the N-
terminus (Endostar)
Stable at low pH (2.5) and at
high temperature (100 ℃)
Solubility: >15 mg/ml
Shelf life: 18 months at 4 ℃
Manufactured in E. coli
Large-scale inclusion body
refolding
0.5 mg/ml, with >50% Endostatin Endu(Endostar)
recovery
10
11. Pipeline Overview
Therapeutic Status
Key Product
Areas Candidate Lead Lead Pre-
IND
Phase Phase Phase New Drug
Discovery Optimization clinical I II III Application
Inflammation Iguratimod tablets Approved
Oncology Oxaliplatin
Oncology Endu combined with NP Therapy
Cardiovascular rh-RGD-Hirudin for injection
Oncology Bendamustine for injection
Cardiovascular Oral fixed dose combination of
amlodipine & irbesartan
SIM-0930 (protein tyrosine kinase
Oncology
inhibitor)
Oncology
SIM6802 (protein tyrosine kinase IND approved
inhibitor)
SIM010603 (protein tyrosine
Oncology
kinase inhibitor)
Oncology SIMBD0801 (MAb)
Cerebrovascular SIM071201
Oncology SIM0710 (PEG-Endostar injection)
Onclogy SIM-817378
12. Simcere R&D Organization
Institute of Recombinant
Institute of Institute of Institute of Institute of Proteins R&D
Discovery Chem., Pharm. Shanghai
Discovery Biologics Vaccine Center
Chemistry & Anal. R&D Center
Biology Research Research
Development
Shanghai Yantai
Prof. Xiaojin Yin, Nanjing Nanjing
Nanjing
Nanjing Nanjing
Beijing
SVP
Dr. Peng Wang,
CSO Dept. of Market Dept. of
Institute of Office of Dept. of Regulatory Dept. of
Res. and
Clinical Intellectual Project Affairs Operation &
Business
Research Properties Management HR
Development
Nanjing
Nanjing Nanjing Nanjing Nanjing
Nanjing Beijing
A staff of ~300, located in Nanjing, Shanghai, Beijing and Yantai
PhD: ~20%; MS: ~60%; 25 staff members with Western training/working experience
Ongoing aggressive recruitment of industrial veterans from US in all R&D areas
Nanjing R&D Center: 200,000 sf
7% of total revenues as R&D budget
13. Strong Track Record
Clinical development:
Over 30 successfully completed clinical trials
Endu Ph IV trial completed in Dec. 2009, with >3,000 patients recruited, the largest clinical
study in China history
Regulatory affairs:
Approximately 100 NDAs/ANDAs obtained
Five (5) INDs filed in 2010 alone
A FIH trial in Australia completed
Endu has been re-registered for marketing authorization in 2010: the first in China
New head of Regulatory Affairs, Mr. Bo Xu (a former SFDA reviewer), has been on board
since 2010
~120 patents and patent applications
Over 100 scientific publications
13
15. Selected Key Partnerships
Innovative Strategic Partnership Traditional In-Licensing
Joint Venture partnership with Merck (2011): OSI Pharmaceutical (2009):
A transformational deal that cements Simcere’s A small molecule protein kinase inhibitor in Phase I
leadership in branded generics market in China development
A strategic partnership with development, Simcere responsible for development and commercialization
registration, manufacturing and sales capabilities in China
Initial focus on cardiovascular and metabolic OSI responsible for ex-China global development
diseases
R&D strategic partnership with BMS (2010):
Epitomics (2009):
Co-development partnership
A humanized rabbit monoclonal antibody in preclinical
A small molecule oncology compound in preclinical development
development
Simcere responsible for development and commercialization
Simcere responsible for development and in China
commercialization in China
Simcere and Epitomics to share cost of development
BMS has option to resume global development (ex- outside of China
China) after Simcere achieves PoC in man
GSK (2006):
Simcere licensed the rights to develop an authorized generic
version of Relenza in China
Product approved in China in 2010
15
16. Key Areas of Partnering Interests
Oncology Flexible deal
Molecular targeted therapies of both small molecules and biologics structures
based on validated or novel mechanism of action Aim to create win-
Cytotoxics differentiated on efficacy and/or tolerability with proof-of- win partnership
concept in man Structure deals to
Early stage opportunities and novel technology platforms that lead to fit partner’s
step change in cancer therapy strategy
Neuroscience Committed to
fostering growth
Cerebrovascular disease treatment and neuroprotectant and sharing
Alzheimer’s Disease – disease-modifying therapies with proof-of- success
concept in man Efficient process
Cardiovascular and Metabolic Disease Identify and
Atherosclerosis, thrombosis, anti-coagulation, anti-platelet, atrial evaluate
fibrillation agents and diabetes opportunity
Infectious Diseases Conduct due
Antibacterias that address bacterial resistance and serious infections diligence and
Antifungals negotiate
agreement
Antivirals – HBV and HCV only
Implement and
Inflammation
manage project,
Rheumatoid Arthritis – disease modifying agents with potential to moving toward
differentiate based on efficacy and/or cost of treatment success
16
17. Value Proposition to Partners
Leverage Simcere’s internal R&D capability to develop partner’s asset in
China under the FDA and SFDA requirements
Accelerate clinical trials indications through faster patient enrollment
Generate critical data package to support global development
Leverage Simcere’s powerful commercial platform to achieve rapid and
broad market access
Utilize Simcere’s experience, resources, leadership and homeland
advantage to penetrate the market
17
18. Simcere’s Commitment
Clear corporate mandate of externalization
Bring products to address significant unmet medical needs in China
through sourcing global innovations
Commitment to fostering partnership and sharing success
Flexible deal structures
Highest standard of corporate compliance and transparency
Experienced management team with proven track record
World-class R&D leadership team with U.S. industry veterans
Clinical Advisory Board with leading thought leaders in the U.S.
18